Generate:Biomedicines, a technology company focused on the intersection of machine learning, biological engineering, and medicine, announced on Thursday that results from its Phase 1 study of GB-0895 will be presented as a late-breaker at the European Respiratory Society International Congress in Amsterdam on 28 September 2025.

GB-0895 is an investigational, subcutaneously administered anti-thymic stromal lymphopoietin (TSLP) antibody engineered with generative AI for the treatment of multiple respiratory diseases.

In the Phase 1 study, 96 patients with mild to moderate asthma were dosed in single ascending dose (Part A) and multiple ascending dose (Part B) cohorts. GB-0895 was well tolerated across a wide dose range of 10 mg to 1200 mg and showcased dose-proportional pharmacokinetics with a prolonged half-life of approximately 89 days. Sustained reductions in eosinophils, FeNO, IL-5, and IL-13 were observed for at least six months, consistent with an anti-TSLP mechanism of action.